Development of Orally Disintegrating Tablets Based on a New Excipient - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Development of Orally Disintegrating Tablets Based on a New Excipient
The authors examine the effectiveness of an excipient comprised of mannitol, polyvinyl acetate, and crospovidone using model actives loperamide hydrogen chloride and caffeine.


Pharmaceutical Technology
Volume 32, Issue 11, pp. 66-70


Figure 3: Porosity and disintegration as a function of compression force using loperamide tablets with 0% Kollidon CL-SF. Kollidon CL-SF is a registered trademark of BASF SE. (ALL FIGURES ARE COURTESY OF BASF SE.)
The hardness of loperamide HCl tablets was slightly reduced by increasing the tableting speed from 20 to 60 rpm, but disintegration time remained constant (see Figure 4).


Figure 4: Hardness and disintegration as a function of tableting speed using loperamide tablets with 0% Kollidon CL-SF. Kollidon CL-SF is a registered trademark of BASF SE. (ALL FIGURES ARE COURTESY OF BASF SE.)
As expected, the disintegration times can be further shortened by the addition of Kollidon CL-SF (1% and 2%), which is accompanied by a tendency toward higher hardness and lower friability. With these formulations, tableting pressures can be increased to 140 MPa without a negative impact on disintegration (see Figure 5).


Figure 5: Impact of additional Kollidon CL-SF on disintegration of loperamide tablets. Kollidon CL-SF is a registered trademark of BASF SE. (ALL FIGURES ARE COURTESY OF BASF SE.)
Surprisingly, even the low-dosed loperamide HCl tablets exhibited an acceptable standard deviation of content (4.98%) and mass (0.53–0.81%), which may be caused by formation of interacting mixtures. There was 94.7% dissolution after 30 min for the loperamide HCl tablets with 1% Kollidon CL-SF.


Table III: Properties of a caffeine tablet.
Caffeine tablets gave similar results: 5.48% content uniformity, 0.98% mass variation, 100.6% dissolution after 10 min (see Table III).

The addition of particular flavors such as chocolate improved the taste of the tablets significantly. Further tests with magnesium stearate instead of sodium stearyl fumarate showed that significantly longer disintegration times were recorded caused by the known lipophilizing effect of this compound (2).

Conclusion

Loperamide and caffeine orally dispersible tablets based on Ludiflash can be manufactured easily via a direct compression process. Optimal tableting pressure was found to be 60–10 MPa because this results in rapidly disintegrating, mechanically stable tablets. Addition of small amounts of Kollidon CL-SF further shortened disintegration times and allowed even higher tableting pressures (60–140 MPa). Tablet characteristics are only slightly influenced by compression speed.

S. Kruse is a laboratory expert, S. Gebert is a pharmaceutical engineer, K. Meyer-Böhm is a research and development (R&D) manager, A. Maschke, PhD, is a R&D manager, and K. Kolter*, PhD, is head of R&D for pharmaceutical excipients, BASF SE, G-EMP-MD-H201, Ludwigshafen, Germany, 67056, tel. + 49 621 6041664, fax; 49 621 6097370,

*To whom all correspondence should be addressed.

Submitted: Apr. 16, 2008; Accepted: Apr.24, 2008.




What would you do differently? Email your thoughts about this paper to
and we may post them to the site.

References

1. R. Bohnacker et al., "Determination of the Disintegration Time of Mouth Melt Tablets with Texture Analyzer Method," Pharm. Ind. 67 (3), 327–35 (2005).

2. S. Rizk et al., "Influence of Lubricant Properties on Compression Behavior and Drug Dissolution Rate of Scleroglucan Hydrophilic Matrix," Int. J. Pharm. 126 (1–2), 57–63 (1995).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
20%
To all process for new products only
13%
To select process for new products only
24%
To select processes for both new and legacy products
20%
Do not use QbD
22%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Inadequate Access to Medicines Puts EU at Risk
FDA Offers Insight on QbD for Modified-Release Products
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
FindPharma Custom Search
Source: Pharmaceutical Technology,
Click here